First-line PD-1/PD-L1 inhibitor plus chemotherapy vs chemotherapy alone for negative or < 1% PD-L1-expressing metastatic non-small-cell lung cancers

被引：0

作者：

Thierry Landre

Gaetan Des Guetz

Kader Chouahnia

Cherifa Taleb

Alain Vergnenègre

Christos Chouaïd

机构：

[1] Hôpital René-Muret,UCOG 93

[2] APHP,Service d’Oncologie Médicale

[3] Centre Hospitalier Delafontaine,Service d’Oncologie Médicale

[4] Hôpital Avicenne,Service d’Oncogériatrie

[5] APHP,Service de Pneumologie

[6] Hôpital René-Muret,undefined

[7] APHP,undefined

[8] Service d’Oncologie Médicale,undefined

[9] Unité d’Oncologie Thoracique,undefined

[10] Centre Hospitalier Intercommunal (CHI) Créteil,undefined

来源：

Journal of Cancer Research and Clinical Oncology | 2020年 / 146卷

关键词：

Non-small-cell lung cancer; PD-L1; Anti-PD-1/PD-L1; Immunotherapy; Meta-analysis; Management; Chemotherapy;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：441 / 448

页数：7

共 50 条

[21] PD-1 and PD-L1 inhibitor toxicities in non-small cell lung cancer
Shankar, Bairavi
Naidoo, Jarushka
JOURNAL OF THORACIC DISEASE, 2018, 10 : S4034 - S4037
[22] Targeting the PD-1/PD-L1 axis for the treatment of non-small-cell lung cancer
Meyers, D. E.
Bryan, P. M.
Banerji, S.
Morris, D. G.
CURRENT ONCOLOGY, 2018, 25 (04) : E324 - E334
[23] Clinical outcomes and biomarker exploration of first-line PD-1 inhibitors plus chemotherapy in patients with low PD-L1-expressing of gastric or gastroesophageal junction adenocarcinoma
Sun, Yu-Ting
Lu, Shi-Xun
Lai, Ming-Yu
Yang, Xia
Guan, Wen-Long
Yang, Li-Qiong
Li, Yu-Hong
Wang, Feng-Hua
Yang, Da-Jun
Qiu, Miao-Zhen
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2024, 73 (08)
[24] Efficacy and Safety of PD-1/PD-L1 Inhibitors Plus Chemotherapy Versus PD-1/PD-L1 Inhibitors in Advanced Non-Small Cell Lung Cancer: A Network Analysis of Randomized Controlled Trials
Li, Xiang
Yan, Shi
Yang, Jichun
Wang, Yaqi
Lv, Chao
Li, Shaolei
Zhao, Jun
Yang, Yue
Zhuo, Minglei
Wu, Nan
FRONTIERS IN ONCOLOGY, 2021, 10
[25] First-line chemoimmunotherapy versus chemotherapy in PD-L1-negative patients with non-small-cell lung cancer
Mengato, Daniele
Cancanelli, Luca
Rivano, Melania
Chiumente, Marco
Di Spazio, Lorenzo
Messori, Andrea
IMMUNOTHERAPY, 2022, 14 (11) : 871 - 877
[26] Combinations of Chemotherapy and PD-1/PD-L1 Inhibitors in Sarcoma
Meghan M. Lynch
Borislav A. Alexiev
Brett A. Schroeder
Seth M. Pollack
Current Treatment Options in Oncology, 2022, 23 : 1861 - 1876
[27] Combinations of Chemotherapy and PD-1/PD-L1 Inhibitors in Sarcoma
Lynch, Meghan M.
Alexiev, Borislav A.
Schroeder, Brett A.
Pollack, Seth M.
CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2022, 23 (12) : 1861 - 1876
[28] Bevacizumab/PD-1 inhibitor plus chemotherapy as first-line treatment of advanced non-squamous non-small-cell lung cancer
Wang, Jing
Chen, Qin
Wang, Xinyue
Huang, Dingzhi
Jiang, Richeng
JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2023, 12 (05)
[29] Non-Small-Cell Lung Cancer Signaling Pathways, Metabolism, and PD-1/PD-L1 Antibodies
Santarpia, Mariacarmela
Aguilar, Andres
Chaib, Imane
Cardona, Andres Felipe
Fancelli, Sara
Laguia, Fernando
Bracht, Jillian Wilhelmina Paulina
Cao, Peng
Molina-Vila, Miguel Angel
Karachaliou, Niki
Rosell, Rafael
CANCERS, 2020, 12 (06)
[30] PD-1/PD-L1 inhibitor use for NSCLC: more irAEs with first-line therapy
Reactions Weekly, 2023, 1980 (1) : 10 - 10

← 1 2 3 4 5 →